At a glance
During this COCA Call, presenters will discuss CDC’s surveillance of MIS-C, updated MIS-C resources for healthcare providers, research that informed those resources, and data related to COVID-19 vaccination and MIS-C.
Overview
Multisystem inflammatory syndrome in children (MIS-C) is a rare but severe condition associated with SARS-CoV-2 infection. The Centers for Disease Control and Prevention (CDC) has been actively involved in MIS-C surveillance and research, and development of MIS-C resources to support the public health and healthcare community. During this COCA Call, presenters will discuss CDC's surveillance of MIS-C, updated MIS-C resources for healthcare providers, research that informed those resources, and data related to COVID-19 vaccination and MIS-C.
Presenters
Angela Campbell, MD, MPH, FAAP, FPIDS, FIDSA
Medical Officer
Multisystem Inflammatory Syndrome (MIS) Unit
COVID-19 Response
Centers for Disease Control and Prevention
Shana Godfred-Cato, DO, FAAP
Medical Officer
Multisystem Inflammatory Syndrome (MIS) Unit
COVID-19 Response
Centers for Disease Control and Prevention
Anna Yousaf, MD
Medical Officer
Multisystem Inflammatory Syndrome (MIS) Unit
COVID-19 Response
Centers for Disease Control and Prevention
Call Objectives
Activity-specific objectives:
- Describe sources of MIS-C surveillance data.
- Identify resources on MIS-C symptoms and what parents and caregivers need to know before and after a diagnosis of MIS-C.
- List key points for healthcare providers to use when talking with families and caregivers about MIS-C.
- Discuss information related to COVID-19 vaccination and MIS-C.
COCA Call Objectives
- Cite background information on the topic covered during the presentation.
- Discuss CDC's role in the topic covered during the presentation.
- Describe the topic's implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
- Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.
Additional Resources
- COVID Data Tracker – MIS-C | CDC
- Multisystem Inflammatory Syndrome (MIS) | CDC
- MIS-C Healthcare Provider Resources | CDC
- Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C) | CDC
- For Parents: Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19 | CDC
- How to Recognize Multisystem Inflammatory Syndrome in Children (MIS-C) (cdc.gov)
- Clinical Overview of Multisystem Inflammatory Syndrome in Children | MIS | CDC
- Multisystem Inflammatory Syndrome in Children (MIS-C) | AAPexternal icon
- Vaccine Adverse Event Reporting System (VAERS) | HHSexternal icon
- About the Clinical Immunization Safety Assessment (CISA) Project | Vaccine Safety Systems | CDC
- American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2 – Henderson – 2021 – Arthritis & Rheumatology – Wiley Online Library
- Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC
- ACIP General Best Practice Guidelines for Immunization | CDC
Continuing Education
To receive continuing education (CE) for WC4520-021022 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – COVID-19 Updates: What Clinicians Need to Know About Multisystem Inflammatory Syndrome in Children, Thursday, February 10, 2022, please visit TCEO and follow these 9 Simple Steps by Monday, March 14, 2022.
To receive continuing education (CE) for WD4520-021022 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – What Clinicians Need to Know About Multisystem Inflammatory Syndrome in Children, Thursday, February 10, 2022,(Web on Demand), please visit TCEO and follow these 9 Simple Steps between Tuesday, March 15, 2022, and Friday, March 15, 2024.
In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME: The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA CME: Credit Designation Statement – LiveThe Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.
CPE: The Centers for Disease Control and Prevention designated this (Knowledge-based) event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA – 4008229-0000-22-101-L04-P and enduring JA – 4008229-0000-22-111-H04-P.
Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.
AAVSB/RACE: This program was reviewed and approved by AAVSB RACE program for 1 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program if you have any comments or concerns regarding this program's validity or relevancy to the veterinary profession.
For Certified Public Health Professionals (CPH)The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.
DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated
Content will not include any discussion of the unlabeled use of a product or a product under investigational use.
CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.
Target Audience
- Physicians
- Nurses
- Pharmacists
- Veterinarians
- Physician Assistants
- Health Educators
- Other Clinicians
Additional Information
- Contact Information: coca@cdc.gov
- Support/Funding: Centers for Disease Control and Prevention, Emergency Risk Communication Branch
- Method of Participation: You may participate in the educational activity by viewing the program information above.